ADC Therapeutics SA (ADCT)
3.67
-0.06
(-1.61%)
USD |
NYSE |
May 22, 16:00
3.66
-0.01
(-0.27%)
Pre-Market: 20:00
ADC Therapeutics Enterprise Value: 232.10M for May 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 22, 2024 | 232.10M |
| May 21, 2024 | 237.87M |
| May 20, 2024 | 274.44M |
| May 17, 2024 | 273.48M |
| May 16, 2024 | 272.51M |
| May 15, 2024 | 276.36M |
| May 14, 2024 | 267.70M |
| May 13, 2024 | 282.14M |
| May 10, 2024 | 292.72M |
| May 09, 2024 | 318.70M |
| May 08, 2024 | 303.31M |
| May 07, 2024 | 278.94M |
| May 06, 2024 | 247.47M |
| May 03, 2024 | 284.74M |
| May 02, 2024 | 270.66M |
| May 01, 2024 | 269.00M |
| April 30, 2024 | 244.16M |
| April 29, 2024 | 251.61M |
| April 26, 2024 | 238.36M |
| April 25, 2024 | 246.64M |
| April 24, 2024 | 274.80M |
| April 23, 2024 | 290.53M |
| April 22, 2024 | 266.52M |
| April 19, 2024 | 269.83M |
| April 18, 2024 | 273.14M |
| Date | Value |
|---|---|
| April 17, 2024 | 289.71M |
| April 16, 2024 | 246.64M |
| April 15, 2024 | 240.85M |
| April 12, 2024 | 242.50M |
| April 11, 2024 | 266.35M |
| April 10, 2024 | 268.83M |
| April 09, 2024 | 274.62M |
| April 08, 2024 | 300.28M |
| April 05, 2024 | 292.84M |
| April 04, 2024 | 268.83M |
| April 03, 2024 | 245.65M |
| April 02, 2024 | 235.72M |
| April 01, 2024 | 246.48M |
| March 31, 2024 | 250.62M |
| March 28, 2024 | 204.69M |
| March 27, 2024 | 180.76M |
| March 26, 2024 | 193.14M |
| March 25, 2024 | 180.76M |
| March 22, 2024 | 208.82M |
| March 21, 2024 | 214.59M |
| March 20, 2024 | 224.50M |
| March 19, 2024 | 219.54M |
| March 18, 2024 | 198.09M |
| March 15, 2024 | 146.09M |
| March 14, 2024 | 142.79M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-178.24M
Minimum
Sep 22 2023
3.297B
Maximum
Jul 02 2020
882.91M
Average
404.15M
Median
Enterprise Value Benchmarks
| Roche Holding AG | 228.95B |
| Novartis AG | 223.96B |
| AC Immune SA | 225.03M |
| CRISPR Therapeutics AG | 2.715B |
| Addex Therapeutics Ltd | 4.824M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -46.61M |
| Revenue (Quarterly) | 18.05M |
| Total Expenses (Quarterly) | 51.42M |
| EPS Diluted (Quarterly) | -0.56 |
| Gross Profit Margin (Quarterly) | 86.10% |
| Profit Margin (Quarterly) | -258.2% |
| Earnings Yield | -75.48% |
| Normalized Earnings Yield | -74.86 |